Aims: The British National Institute of Clinical Excellence (NICE) guidelines recommend to use drug-eluting stents (DES) instead of bare-metal stents (BMS) only in lesions >15 mm in length or in vessels <3 mm in diameter. We analyzed the impact of stent length and stent diameter on in-stent restenosis (ISR) in the BASKET-PROVE study population and evaluated the cost-effectiveness of DES compared to BMS.
recommendation of a BMS in coronary arteries with a diameter ≥3 mm and lesion length ≤15 mm. 10 However, this is based on subgroup analysis or registry data from trials comparing BMS vs DES 9, 11, 12 and was never investigated in a large study where only patients needing large coronary stents were included. In the NICE technology appraisal costutility model, the use of DES in long lesions or small vessels seemed to be cost-effective at a price difference between DES and BMS of less than 300£. The corresponding ICERs per QALY gained were 47 000£ and 25 000£, respectively.
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In the multicenter randomized BASKET-PROVE trial, the performance of a BMS against a first-generation (Cypher, Cordis, Johnson and Johnson, Miami Lakes, FL, USA) and a second-generation (Xience, Abbott Vascular, Abbott Laboratories, IL, USA) DES was compared in allcomer patients with coronary vessel diameters ≥3 mm. While the overall safety endpoint of cardiac death and myocardial infarction was similar between patients treated with BMS vs DES, the rate of target vessel revascularization (TVR) was increased in patients treated with a BMS. 13 In the present analysis, we investigated the influence of stent length and diameter on ISR in the BMS and the DES arm in this population, as well as the cost-effectiveness of DES compared to BMS in short lesions in large coronary arteries.
| METHODS
The study design and methods have been described in detail previously. 14 In brief, patients with stable coronary artery disease or with acute coronary syndrome (ACS) who were referred for coronary angiography/angioplasty to the participating centers were eligible for enrollment in the BASKET-PROVE trial. Patients were included in the trial if they received at least one stent with a diameter ≥3 mm regardless of the stent length. There were no restrictions regarding the number of treated lesions or vessels, the length of treated lesions, or the number of stents implanted. Patients with cardiogenic shock, ISR, stent thrombosis, saphenous vein graft disease, unprotected left main coronary artery, oral anticoagulation, planned noncardiac surgery or known intolerance to or suspected noncompliance with long-term antiplatelet therapy were excluded from the trial. In addition, patients requiring stents larger than 4.0 mm in diameter were excluded because the sirolimus-eluting stent used in this trial (ie, Cypher Stent) was only available to a maximum diameter of 4.0 mm. If it became necessary during the procedure that a stent <3.0 mm had to be implanted in addition to the larger stent, this was allowed but these segments were not considered in the present analysis All patients provided written informed consent.
Patients were randomly assigned in a 1 CHF and 1151 CHF with a price gap of 285 CHF. As a peculiarity of the Swiss-DRG system, there is no difference in hospital reimbursement between the use of a DES or BMS, so we decided to generate two cost models, the "swiss-specific model" and the "price-gap model".
In the latter, the price gap of 285 CHF per DES implanted directly affected healthcare costs in all procedures. Expenditures for clopidogrel
were not considered, as all patients of the study population received dual antiplatelet therapy over 12 months. The cost-effectiveness was calculated for the follow-up period of 2 years, and due to this short period of time, costs were not discounted. Healthcare utilities were measured as QALYs gained and target lesion revascularizations (TLR)
avoided. DES were considered cost-effective if the ICERs were below an arbitrary threshold of ≤50 000 CHF per QALY gained and ≤10 000
CHF per TLR avoided.
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| Statistical analysis
Time to ISR was calculated as the number of days between the initial percutaneous coronary intervention (PCI), at which a patient received a DES or a BMS, and the TLR. Patients without an event during the follow-up period were right-censored at the last follow-up date. If two stents were used in one segment, it was assumed that they were used for the same lesion.
As a first approach, the data were explored graphically by KaplanMeier curves. It is important to note, however, that these graphics do not capture the full complexity of the data and of the statistical models used. Because the analysis was performed on the segment level (with more than one treated segment in some of the patients), we used mixed-effects Cox models with patient as random factor to account for the nonindependence of segments from the same patient. We fit- For the cost-effectiveness analysis, QALYs were derived from the integrated EQ-5D questionnaires over the follow-up period of 2 years.
Missing utility data were complemented with simple imputation. We used ordinary, nonparametric bootstrapping (with 9999 replicates) to estimate the difference in average costs, the difference in aver- 
| RESULTS
A total of 2278 patients with a total of 3174 stented segments (with a maximum of six segments per patient) were included in the analy- There were no significant differences in baseline characteristics between patients suffering from an ISR and patients without ISR (Table 1) except for a higher number of stents per patient, a higher number of stented segments and less STEMI patients in the group with ISR.
The risk of ISR was significantly higher in segments with a BMS compared to segments with a DES (Figure 1) The number (n) and percentage of patients (%) with measurements are shown for categorical variables, the mean and the standard deviation (mean ± SD) are shown for continuous variables.
interaction between stent type and stent length). Figure 3 shows the corresponding Kaplan-Meier curves. TLR avoided, respectively. Per QALY gained the probability of DES being cost-effective was 52.0%, per TLR avoided 88.2% (Figures 6 and 7 ).
| DISCUSSION
The main finding of our study is that in patients in need of large coronary stents, the strongest predictor of ISR is the use of a BMS. Moreover, the risk of ISR increased with increasing stent length and decreased with increasing stent diameter in patients in need of large coronary stents. Notably, even in the subgroup of segments with stent length ≤15 mm, for which the NICE guidelines recommend against the use of a DES, the ISR rate was significantly higher in patients with BMS compared to patients with DES. Other cofactors like renal failure or DM were not associated with ISR in our study.
F I G U R E 1 Kaplan-Meier curves for instent restenosis (ISR) events by stent type (DES vs BMS). After 2 y, an ISR occurred in 5.41% of BMS and 0.76% of DES segments T A B L E 2 Hazard ratio (HR) estimates from a mixed-effects Cox model for in-stent restenosis in BASKET-PROVE

The advantage of DES over BMS in preventing ISR has been
shown in several randomized trials and meta-analyses. [1] [2] [3] [4] [5] [6] [7] [8] However, this has never been investigated in a randomized trial in patients receiving only stents in large (ie, ≥3 mm) coronary arteries. Steinberg et al. 9 compared DES to BMS in 466 patients receiving stents with a diameter ≥3.5 mm using propensity score matched registry data.
They found no difference between patients with large coronary vessels treated by BMS or DES regarding TLR after 1 year. However, the study group was relatively small and the incidence of TLR after 1 year was low (3.5% in the BMS arm vs 3.4% in the DES arm). The study by Steinberg et al. and other smaller subgroup analyses 11, 12 with similar results, as well as the influence of the BASKET trial, in which DES were only found to be cost-effective in long lesions and small vessels 6 led to the current NICE guidelines. 10 These guidelines recommend using a DES in small coronary arteries or long lesions (<3 mm diameter or lesion length >15 mm) and, as a consequence, a BMS in large coronary arteries with short lesions (≥3 mm and ≤15 mm). According to our results, these guidelines need to be challenged. In our large randomized trial including only patients in need of large coronary stents, the strongest predictor of ISR was the use of a BMS. Moreover, one millimeter increase in stent length was associated with a 2% higher risk of ISR and one millimeter increase in stent diameter was associated with a 76% lower risk of ISR. This indicates that even in patients needing exclusively large coronary stents, there is a strong association between both stent diameter and stent length with ISR. However, our subgroup F I G U R E 4 Incremental cost-effectiveness regarding QALYs gained in patients with stented segments ≤15 mm using the Swissspecific model (top) and the price-gap model (bottom). The numbers in the corners of the panels indicate the percentage of data points lying in that figure quadrant F I G U R E 5 Incremental cost-effectiveness regarding TLRs avoided in patients with stented segments ≤15 mm using the Swiss-specific model (top) and the price-gap model (bottom). The numbers in the corners of the panels indicate the percentage of data points lying in that figure quadrant F I G U R E 6 Probability of cost-effectiveness in relation to willingness to pay to gain 1 QALY with the use of DES compared to BMS in patients with stented segments ≤15 mm for the two cost models analysis showed that stent length (>15 mm vs ≤15 mm) did not significantly change the effect of DES compared to BMS regarding ISR. Even in the subgroup with lesions ≤15 mm, there was a significant benefit of DES compared to BMS. The incidence of ISR in the BMS arm was comparable to previous work, 9 but the ISR rate in the DES arm was low in our study (0.74%). This might be due to the fact that we excluded saphenous vein graft interventions (a population normally overrepresented in patients receiving large stents and associated with high rates of ISR) and re-angiographies were only performed on clinical grounds.
Leaving a gap between two stents was also a risk factor for ISR.
This has been shown in previous studies 20 and is probably due to balloon injury of the vessel wall without stent coverage.
Diabetes mellitus and renal failure, both shown to influence ISR in studies including patients with smaller vessels/stents, [21] [22] [23] were not associated with ISR in our study population. These parameters may be more relevant for ISR in patients with smaller vessels/stents.
In BMS patients, ISR has been reported to occur after a median time of 90 days (STEMI patients) and 125 days (non-MI patients) after stent implantation, respectively. 24 There is a paucity of data on the timing of ISR related to DES. In one study of 39 ISR cases associated with DES, the mean time from PCI to ISR detection was approximately 12 months. 25 In our study, median time to ISR was around 5 months in the BMS arm, which corresponds to previous work. 19 Median time to ISR in patients with a DES was significantly longer (around 9 months).
The time frame to restenosis after DES may indeed be longer than that after BMS because antiproliferative drugs can delay the biological response to injury.
The findings of this study clearly show the clinical advantage of DES vs BMS in large coronary arteries and even short lesions, but, due to higher DES prices, cost-effectiveness is debatable. In our study, in the Swiss Health Care System, the use of DES was costsaving, without a significant effect on QALYs. Using TLR avoided as a health-utility parameter, DES were dominant (more effective, less costly) in 70.5% and cost-effective with a probability of 99.2% at a threshold of 10 000 CHF per TLR avoided. The price-gap model, in which the price premium between DES and BMS affected healthcare costs in all PCIs, DES would only be cost-effective in regard to QALYs gained in 52.0%, but looking at TLR avoided with a 10 000 CHF threshold they can be considered cost-effective with the high probability of 88.2%. The lack of a significant difference in QALYs between DES and BMS is well known and mainly due to the fact that without a mortality-benefit, no life years are gained and only a little increase in quality of life (QoL) after baseline and TLR. vs 41%). 28 Furthermore, the ARR and RRR in our subgroup in regard to TLR were 4.6%, and 86%.
The NICE Assessment Group cost-effectiveness model examined the cost utility of DES in long lesions (>15 mm) and small vessels (<3 mm) with a price gap of <300£ in which DES were found cost-effective. 10 With the price-gap model, which considers a price premium in all procedures, a coarse comparison with the NHS might be suitable. The results of our model with a high probability of DES being cost-effective in regard to TLR avoided, even in short lesions in large coronary arteries, should prompt the NICE to adjust the costeffectiveness determining factors in their model (price gap, absolute risk of revascularization in BMS and higher relative risk reduction for TLR when using DES).
In conclusion, we found the strongest independent predictor of ISR in patients receiving large coronary stents to be the use of a BMS, which is in contrast to previous work. For Switzerland in specific, as well as in the price-gap model, DES in large coronary arteries and short lesions do not only show a clear clinical benefit, but they also have a high probability of being cost-effective. Altogether, these findings challenge the recommendation of NICE to use a DES only in vessels <3.0 mm or in lesions >15 mm.
| Limitations
A limitation of the current retrospective analysis, and in particular of the subgroup analysis, is that the original study was powered for differences in major cardiovascular events (ie, combination of cardiovascular death and nonfatal myocardial infarction). Moreover, no intravascular imaging in patients presenting with ISR was performed.
Therefore, nothing can be said about the morphologic pattern of ISR.
F I G U R E 7 Probability of cost-effectiveness in relation to willingness to pay to avoid one TLR with the use of DES compared to BMS in patients with stented segments ≤15 mm for the two cost models
Re-angiographies were only performed on clinical grounds. ISR rates are usually higher when systematic re-angiographies are performed.
In regard to the cost-effectiveness analysis, the main limitations are the fact that costs were (1) modeled and (2) this was performed retrospectively. Furthermore, the benefit in terms of the number of QALYs gained and TLRs avoided when using DES vs BMS is likely to be underestimated because the difference in QALYs/TLRS was only calculated over the duration of the study and not extrapolated to the whole remaining lifetime of the patients.
